GLP-tox study reinforces favorable safety profile of Tiprelestat Phase II Study in Pulmonary Arterial Hypertension (PAH) to be initiated by Stanford University in mid-2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback